Sensei biotherapeutics to present initial clinical data from dose escalation trial of sns-101 at 2023 sitc annual meeting

Boston, oct. 25, 2023 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced it will present initial safety and pharmacokinetic monotherapy clinical data from its phase 1/2 trial of sns-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint vista (v-domain ig suppressor of t cell activation), in a late-breaking poster presentation at the society for immunotherapy of cancer (sitc) 38th annual meeting, being held in san diego, calif., from november 1 - 5, 2023.
SNSE Ratings Summary
SNSE Quant Ranking